News >

Personalized Medicine Progressing in Premenopausal Breast Cancer

Caroline Seymour
Published: Wednesday, Apr 17, 2019

Joyce A. O’Shaughnessy, MD

Joyce A. O’Shaughnessy, MD

Eight-year follow-up findings from the TEXT and SOFT trials provided considerable insight into the use of adjuvant endocrine therapy for women with premenopausal hormone receptor (HR)–positive breast cancer, said Joyce A. O’Shaughnessy, MD. However, more follow-up is needed to fully understand how stopping therapy at 5 years will impact disease-free survival (DFS).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication